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Diabetes mellitus is a highly prevalent metabolic condition in ageing societies associated with high
levels of morbidity, multiple therapies, and functional deterioration that challenges even the best of
health care systems to deliver high-quality, individualized care. Most international clinical guidelines
have ignored the often-unique issues of frailty, functional limitation, changes in mental health, and
increasing dependency that characterize many aged patients with diabetes. A collaborative Expert Group
of the IAGG and EDWPOP and an International Task Force have explored the key issues that affectD, FRCP, Institute of Diabetes
itchin Road, Luton LU2 8LE,
lair).
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** Members of the International Task Force/ Invited Experts e attending
y Roundtable: Invited Experts e participating via Audio Teleconference
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A. Sinclair et al. / JAMDA 13 (2012) 497e502498diabetes in older people using a robust method comprising a Delphi process and an evidence-based
review of the literature. Eight domains of interest were initially agreed and discussed: hypoglycemia,
therapy, care home diabetes, inﬂuence of comorbidities, glucose targets, family/carer perspectives,
diabetes education, and patient safety. A set of “consensus” statements was produced in each domain of
interest. These form a foundation for future policy development in this area and should inﬂuence the
clinical behavior and approach of all health professionals engaged in delivering diabetes care to older
people.
Published by Elsevier Inc. on behalf of the American Medical Directors Association, Inc.Up to 1 in 5 older people have diabetes, and a similar proportion
may have undiagnosed diabetes. This is not a trivial disease and poses
many signiﬁcant challenges to the delivery of effective care.
There is ample proof of the economic, social, and health burden of
diabetes in the elderly population. Despite this recognition, diabetes
care of older people has been relatively neglected in the medical
literature, with few reports of large randomized clinical trials in older
patients. In addition, there is little evidence of structured diabetes
care in many national diabetes care systems and virtually no speciﬁc
provision for those who are housebound or living in institutional
care.
The effective management of the older patient with diabetes
requires an emphasis on safety, diabetes prevention, early treatment
for vascular disease, and functional assessment of disability because
of limb problems, eye disease, and stroke. Additionally, in older age,
prevention and management of other diabetes-related complications
and associated conditions, such as cognitive dysfunction, functional
dependence, and depression, become a priority.
Various surveys suggest evidence of inequalities in diabetes care
owing to variations in clinical practice, particularly in relation to older
people. This may be manifest as lack of access to services and inad-
equate specialist provision that lead to poorer clinical outcomes and
patient and family dissatisfaction.
Patient safety is an a priori issue for managing older people
with diabetes but is often compromised by inappropriate treat-
ment choice, suboptimal specialist follow-up, and patient-centered
issues, such as the development of cognitive dysfunction or
depressive illness. Both of these conditions are more common in
older people and may in fact be directly associated with the
presence of diabetes. Depression is often not recognized and
inadequately treated. Social isolation may be a feature of many
older people with diabetes, particularly if they have few relatives
or have mental health problems, and providing a well-supported
social network is important.
We recognize there is confusion within health care organizations
and their providers on what the terms “elderly” or “older” actually
represent. We have taken a “global” perspective in this Position
Statement, and, as we are attempting to address issues in more
vulnerable older patients, we have limited our scope to those 70 years
and older.
We also understand that older people are not a homogeneous
group of individuals, but have varying levels of cognitive and
functional ability and an often complex set of health and social care
needs depending on the state of development of national health
care services and a patient’s access to them. Although an older
person with diabetes has a high likelihood of being well and en-
joying a good quality of life, many are functionally dependent or
have evidence of cognitive problems, which alters goals of care and
inﬂuences management strategies. This Position Statement
attempts to embody these aspects in the conclusions and state-
ments given.
We feel that it is timely to establish a collaborative initiative
between key international diabetes and gerontological organizations
to enhance diabetes care for older people worldwide. This PositionStatement represents the ﬁrst stage in developing such a global
initiative. It was produced to inﬂuence the clinical behavior and
approach of all health professionals engaged in delivering diabetes
care to older people.
Background Aims
Following a round table discussion by key participants at the
European Association of for the Study of Diabetes in Rome in
September 2008, we identiﬁed a list of priorities and developed
a concerted action plan for enhancing diabetes care in older people.
This Position Statement on diabetes in older people is designed to
give an overview of the present state of diabetes care of this group of
people. In addition, the statement will outline a consensus view on
the perceived priorities for improving diabetes care and achieving the
best possible clinical outcomes during the next decade. Diabetologists
from around the globe and both the International Association of
Gerontology and Geriatrics and the European Diabetes Working Party
have been involved in developing this work.
Purpose of the Position Statement:
(1) Arrive at a consensus on howwe approach the management of
key issues of diabetes care for older people.
(2) Identify a series of key areas for diabetes-related surveys and/
or audits of clinical care within a range of countries. These may
take the form of surveys of particular drug usage, mortality and
comorbidity rates, models of care, and use of clinical guidelines
in clinical decision making.
(3) Recommend up to 3 to 4 research areas that could be consid-
ered for further investigation using selected research tools, and
that could form the basis of one or more collaborative research
proposals.Methodology and Preparation for Consensus Roundtable
An expert roundtable was organized in June 2010 in Frankfurt as
an opportunity to critically discuss and evaluate views and experi-
ence of some of the complex issues of diabetes in old people. This
group communication process was complemented by 2 audio tele-
conferences with other global experts in the ﬁeld. An audio record of
all discussions was made to assist the moderator (A.S.) to produce
a draft report of the proceedings.
An important purpose was to arrive at a consensus on how we
approach the management of signiﬁcant issues including those that
require further study (see Figure 1). We agreed that by deﬁning at
least 2 recommendations per domain based on this process we
would have a workable set of conclusions on which to base the
Position Statement. Discussants participated in a brief Delphi
process, combined with a traditional evidenced-based approach
(see Appendix A at www.jamda.com), which aimed to address the
main areas from several perspectives. We chose 4 perspectives for
each of the domains of interest (to provide an initial structure) but
participants in the roundtable discussion had the opportunity to
able 1
verall Ranking Domains through 1st and 2nd Stage Processes
Domain Rankinge1st stage* Rankinge2nd stage**
Hypoglycemia 5 3
Therapy 7 5
Care home diabetes 8 5
Inﬂuence of co-morbidities 1 2
Glucose targets 3 1
Family/carer perspectives 4 8
Diabetes education 2 5
Patient safety 5 3
Nutrition***
Hypertension***
rade 1, highest; Grade 8, lowest.
*After Roundtable Discussion only.
**After participation of teleconference experts.
***Additional domains suggested by several participants but not graded highly
nough to be included within the eight chosen.
A. Sinclair et al. / JAMDA 13 (2012) 497e502 499deﬁne other perspectives that needed to be considered. Throughout
the whole process, each participant was able to contribute
a perspective or comment at any stage.
Fig. 1. Post consensus meeting tasks to include evidence-based review as appropriate.
The 4 perspectives were:
(1) Recognizing and Deﬁning the Problem
(2) Determining the Strategy for Solving the Problem
(3) Deﬁning the Criteria That Tests the Solutions
(4) Evaluating the Solutions in Clinical Practice
Eight domains of interest were initially agreed and discussed:
hypoglycemia, therapy, care home diabetes, inﬂuence of comorbid-
ities, glucose targets, family/carer perspectives, diabetes education,
and patient safety. For those participants joining for the teleconfer-
ence only, a brief summary of each domain was prepared by the
moderator and each participant was given an opportunity to
contribute further.
We partly addressed the judgmental issue by asking participants
to rank their level of agreement with each of the 4 perspectives ac-
cording to the following scale (which was discussed and agreed in
advance):
The deﬁnitions of each grading scale are given in Appendix B.
The moderator used a “voting” system when ﬁnal comments and
solutions were being offered so as to reach consensus. After the
conference weekend, the moderator produced a draft report and
provided all participantswith a chance tomake further contributions.
These were received, tabulated, and redistributed to members, and
a second roundtable and international teleconference was held in
Oxford, UK, in January 2011. A ﬁnal consensus was then agreed.
Ranking the Domains of Enquiry
At the start of the roundtable, participants ranked the order of
importance of the domains. For this part only, we show the inﬂuenceT
O
G
eof global experts in modifying the emphasis of the ranking grades.
The overall ranking is shown in Table 1.Consensus Statements According to Each Domain
Assessment of Domains e In Order of Final Ranking
Each domain was discussed in detail during the moderated
discussions (available on request). The following statements were
agreed by consensus and a comment given in each case. These
statements pertain to patients 70 years and older.Glucose Targets
Consensus statements
(1) The clinician must consider individual comorbidities, and
cognitive and functional status when determining what
glucose goals should be agreed with the patient and/or
carer.
(2) In general, on treatment, an HbA1c target range of 53 to 59
mmol/mol (HbA1c 7.0%e7.5 %) should be aimed for.
(3) To reduce the risk of hypoglycemia, no patient should have
a fasting glucose on treatment of less than 6.0 mmol/L: “Not
below 6.”
(4) No patient should commence glucose-lowering therapy with
drugs until the fasting glucose level is consistently 7 mmol/L or
higher: “Not before 7.”
(5) Low blood glucose states (levels of glucose of <5.0 mmol/L)
should be strictly avoided.
(6) A random glucose level higher than 11.0 mmol/L should be
avoided to minimize symptoms and reduce the risk of other
diabetes-related complications.
These values are a guide to treatment and in cases of functional
dependence, care home residency, dementia, end-of-life care, and
other high dependency states, they may need adjusting to reduce
the risk of hypoglycemia and to enhance patient safety.Inﬂuence of Comorbidities
Consensus statements
(1) Because of the high risk of associated comorbidities in older
people with diabetes, we recommend that regular CGA
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related functional loss and the impact of disability.
(2) Older people with diabetes may have varying levels of nutri-
tional impairment that may inﬂuence andmodify the impact of
other comorbidities: a nutritional screening assessment tool
should be used routinely.
(3) In patients with hypertension, the blood pressure threshold for
treatment is 140/80 mm Hg, and 150/90 mm Hg in those
subjects 75 years and older; a lower systolic blood pressure
threshold may be appropriate in those with evidence of renal
impairment (estimated glomerular ﬁltration rate [eGFR] <60
mL/min/1.73 m2).
(4) An acceptable blood pressure target in functionally dependent
patients with diabetes is below 150/90 mm Hg.
(5) Screening for renal impairment in all newly diagnosed patients
with diabetes should be carried out; annual testing of the eGFR
is recommended.
Patient Safety
Consensus statements
(1) Increasing age and progressive functional loss pose signiﬁcant
risks for patient safety.
(2) The close relationship between diabetes and impaired func-
tional status requires all patients to have an assessment of both
physical and cognitive function using the CGA, so as to maxi-
mize independence, self-management ability, and safe adher-
ence to therapy.
(3) Regular screening for mood disorder, cognitive impairment,
and hearing and visual loss (annually as a minimum) is
necessary to enhance patient safety and alert the physician to
the need for additional supportive care.
(4) Avoid polypharmacy and use simpliﬁed (once-daily where
possible) treatment regimens to achieve acceptable glucose
targets; depending on diabetes control and what other comor-
bidities are present, the priority list of medications should
include a statin, an angiotensin-converting enzyme inhibitor,
and a glucose-lowering agent.
Delayed treatment and undertreatment are also important
considerations.Hypoglycemia
Hypoglycemia is deﬁned for the purpose of this statement as
a blood glucose level less than 4 mmol/L.
Consensus statements
(1) In older people, hypoglycemia is a highly prevalent and
underrecognized disorder with severe consequences (eg,
falls, cognitive impairment, hospital admission, and so
forth).
(2) Older people with diabetes on a longer-acting sulphonylurea or
an intensive insulin regimen are at high risk of hypoglycemia:
risk is increased in those with polypharmacy, cognitive
impairment, malnourishment, and those recently discharged
from hospital or residing in a care home.
(3) A focused education strategy needs to be used and imple-
mented for both patients and carers to decrease the risk of
hypoglycemia.
(4) Hospital admission for hypoglycemia should trigger the need
for diabetes specialist review.Therapy
Consensus statements
(1) All patients should participate as actively as possible in
a tailored physical activity program involving resistance
training, balance exercises, and cardiovascular ﬁtness
training.
(2) In view of their limited beneﬁts, restrictive diets should be
avoided in those patients 70 years and older, and in those with
undernutrition.
(3) Metformin can be considered as ﬁrst-line glucose-lowering
therapy in older people with type 2 diabetes, and as an adjunct
to insulin therapy in those recommended for combination
therapy.
(4) In those patients at higher risk of hypoglycemia, sulphonylurea
therapy should be avoided.
(5) In selected patients, a basal insulin regimen may be safer in
terms of hypoglycemia risk than a basal/bolus or premixed
insulin regimen.
(6) In selected older patients not in target or where there is poor
tolerance to the glucose-lowering agents, the use of a dipep-
tidyl peptidase 4 (DPP4) inhibitor can be considered as second-
line therapy.
(7) In subjects who are obese (body mass index [BMI] >35), or
where there is poor tolerance or lack of response to other
agents, a glucagonlike peptide 1 agonist can be considered as
both second-line and third-line therapy.
(8) In selected patients not at high risk of heart failure or of bone
loss or a previous diagnosis of osteoporosis, who have no
history of bladder cancer, treatment with pioglitazone can be
considered as second-line therapy after metformin.
Diabetes in Care Homes
Consensus statements
(1) Diabetes care policies for care homes are recommended but
the focus of treatment should be individualized for each
resident.
(2) The major aims of caring for residents with diabetes are (1)
prevent hypoglycemia, (2) avoid acute metabolic complica-
tions, (3) decrease the risk of infection, (4) prevent hospitali-
zation, and (5) introduce timely end-of-life care and Advanced
Care Directives. There should be a speciﬁc “individualized”
diabetes care plan for each resident with diabetes and this
requires regular review.
(3) A regulatory framework needs to be in place to ensure that
care homes provide access to a diabetes educational course
for staff so as to maintain clinical and social care standards
that are aligned to the health and social care needs of each
resident.
(4) All stakeholders need to be aware that residents with diabetes
have a high prevalence of pressure ulcers of the lower
extremity, infection, and pain and these need timely recogni-
tion and management.Diabetes Education
Consensus statements
(1) Diabetes educational approaches should be aligned with the
cognitive and functional status of older people andmay require
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tional support for carers.
(2) Diabetes education should address the ability of patients (and/
or carers) to manage medication including insulin therapy.
(3) All patients and their carers should receive educational advice
about minimizing hypoglycemia and avoiding hospital
admission.
(4) Impairment in cognitive function (which in itself may be
a complication of diabetes) may impede self-care capacity of
older individuals with diabetes.
(5) Enhancing access (communication, wheelchair compatible,
transport) to local available educational programs should be
emphasized where possible.
(6) Every health care episode (contact) with older people with
diabetes should be viewed as an opportunity to educate both
the patient and family member (or carer). This should include
review of self-management skills, metabolic targets, avoidance
of hypoglycemia, “sick-day” rules, and nutrition.
(7) Media campaigns to highlight the special requirements and
needs of older people with diabetes should be promoted.Family/Carer Perspectives
Consensus statements
(1) Education and support for caregivers should help to keep older
functionally dependent or disabled people with diabetes at
home and may be associated with reduced health and social
care costs.
(2) There needs to be greater recognition of the important roles of
family and nonprofessional caregivers in managing older
people with diabetes.
(3) There needs to be greater recognition of the impact of caring on
caregivers in terms of their own unrecognized health and social
care needs.
(4) Identiﬁed family members and other nonprofessional people
responsible for providing care require an assessment of their
abilities and skills to provide safe and effective diabetes care.Conclusions
This is the ﬁrst comprehensive expert-based review of the avail-
able evidence for the management of diabetes in older people in
which recommendations are developed through a precise methodo-
logical procedure complemented by consideration of the medical
literature.
The roundtable discussion and international teleconference has
established a number of key survey areas that should be developed,
and these are summarized as follows:
(1) Deﬁning the most appropriate pattern of ﬁrst-line and second-
line therapy in type 2 diabetes for older people, and the role of
DPP4-inhibitors and incretin therapies
(2) The prevailing model of diabetes care (eg, mainly primary care
or specialist-based, and so forth)
(3) Hospitalization rates from both domestic and care home-
ebased settings
(4) Patterns of disability, rates of cognitive dysfunction and
disability among older individuals with diabetes.This consensus has also provided information on the major
research areas within diabetes of old age that need to be addressed.
These are summarized in priority order as follows:
(1) The use of exercise-, nutrition-, and glucose-lowering therapies
in the effective management of type 2 diabetes in older people
(2) Practical community-based interventions to reduce
hospitalization
(3) Methods to decrease hypoglycemia rates in various clinical
settings
(4) Health economic evaluations of metabolic treatment
(5) Interventions to delay/prevent diabetes-related complications
that are important in older age, such as cognitive impairment
and functional dependence
(6) Development of technical devices that help to maintain
autonomy and safety for older people with diabetes
Finally, 4 key conclusions emerge from this work and can be
summarized as follows:
(1) Using a Delphi-based method, we were able to identify a series
of statements and recommendations in important key areas of
diabetes management of older people.
(2) Although experts in geriatric diabetes have a major focus on
the effects of diabetes on functional status and well-being, our
group of experts have clearly identiﬁed glucose targets as
a fundamental issue to be addressed.
(3) This consensus statement also highlights other key areas of
signiﬁcant impact in older people such as hypoglycemia,
diabetes-related complications that become a priority in older
age (cognitive impairment and functional dependency), ther-
apeutic issues, the challenges of care home diabetes, and the
importance of diabetes education.
(4) To make progress in this often-neglected area, we require this
Position Statement to lay the foundation of enhanced care for
older people with diabetes on a worldwide scale.
We anticipate that the next step in this international collaborative
work will be to organize a multicenter clinical audit of diabetes care
within countries in all the continents.Dedication
This Position Statement is dedicated to the memory of Dr Ulrich
Vischer (deceased March 19, 2012, aged 54 years), a member of the
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Strongly agree [ 6
You believe that the evidence for making this statement is very
robust and agrees entirely with your clinical experience.
Agree [ 5
Your analysis of the evidence combined with your clinical expe-
rience is sufﬁcient for you to accept this grading for the conclusion/
statement in question.
Mildly agree [ 4
When you have considered all the information at your disposal,
combined with your own views and experience, this is the most likely
fair grade to adopt.Mildly disagree [ 3
When you have considered all the information at your disposal,
combined with your own views and experience, it is your impression
that you are not able to accept this conclusion.
Disagree [ 2
Your analysis of the evidence combined with your clinical expe-
rience is sufﬁcient for you to reject this conclusion.
Strongly disagree [ 1
You believe that the evidence for making this statement is very
weak and does not agree at all with your clinical experience.
